Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-García, Nicla La Verde, James Michael Orcutt, Marina Elena Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortés, Antonio Llombart‐Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue–Geile
Abstract
After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there.
Topics & Concepts
TrastuzumabNeratinibMedicineSurgical oncologyPaclitaxelOncologyBreast cancerInternal medicineChemotherapyNeoadjuvant therapyCancerHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyMonoclonal and Polyclonal Antibodies Research